As shown for CLL and Acute-Lymphoblastic-Leukemia (ALL), glucocorticoids are being used as therapeutic agents [60] are known to inhibit glycolysis and have an effect on GLUT-1 emphasizing the targeting of glycolytic metabolism as therapeutic strategy and suggesting that Dasatinib resistant samples might be more sensitive to glucocorticoids than Dasatinib sensitive samples [14, 61, 62]. The gene discussed is SLC2A1; the disease is acute lymphoblastic leukemia.